Valo Health, Inc., a company pioneering the use of human data and AI to accelerate drug discovery and development, announced the appointment of Rita Kale as Chief Financial Officer (CFO). Rita brings more than two decades of global finance leadership in biopharma, diagnostics, and technology-enabled healthcare.
“We are proud to welcome Rita Kale as Valo’s Chief Financial Officer during such a pivotal time at Valo,” said Brian Alexander, MD, MPH, CEO of Valo Health. “Rita’s deep financial expertise and proven track record of strategically scaling organizations make her an invaluable addition to our leadership team. Her ability to align financial strategy with scientific innovation will be instrumental as we accelerate our mission to transform drug discovery and deliver meaningful impact to patients in the future.”
Health Technology Insights: Adial Pharma Announces $2.86 Million Warrant Inducement Deal
Rita previously served as CFO and Head of Corporate Management at Foundation Medicine, where she played a key role in driving product expansion and operational improvement. Earlier in her career, she held senior finance leadership roles at the Roche Group across Asia-Pacific and Sub-Saharan Africa; served as country CFO in South Africa and India; and led finance for Global Product Strategy in Switzerland. In these positions, Rita led strategic capital allocation and drove major business initiatives across complex healthcare markets, successfully securing funding for multiple product launches while accelerating organizational growth and scaling operations. Rita also serves on the board of CareMetx, a leading patient access services company.
Health Technology Insights: TOMI Environmental Secures $3 Million Life Sciences Integration Deal
“I’m thrilled to join Valo at such a transformative time for the company,” said Rita Kale. “Valo’s vision, platform, and team are outstanding. I look forward to combining corporate strategy and operational execution to help accelerate our mission.”
Valo is transforming drug discovery through AI-enabled human causal biology and predictive chemistry. The company advances its own pipeline of therapeutic candidates, and partners with pharmaceutical companies to accelerate their pre-clinical R&D. By integrating Valo’s early R&D capabilities with the clinical development expertise and scale of its pharmaceutical partners through a fractional portfolio model, Valo aims to deliver more transformative medicines to patients faster.
Health Technology Insights: Herantis Pharma Announces Successful Completion of Six-Month Glp Toxicology Study of Her-096
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
